28
Participants
Start Date
August 31, 2025
Primary Completion Date
March 31, 2026
Study Completion Date
March 31, 2026
EG-007
A Repurposed Drug
Pembrolizumab 100 mg/4 mL (25 mg/ml) Injection
Pembrolizumab will be provided as a sterile, preservative-free, clear to slightly opalescent, colorless to slightly yellow solution that requires dilution for intravenous infusion. Each vial contains 100 mg of pembrolizumab in 4 mL of solution.
Lenvatinib Capsules
Lenvatinib will be provided as 4-mg and 10-mg capsules. Lenvatinib is formulated with calcium carbonate, mannitol, microcrystalline cellulose, hydroxypropyl cellulose, low-substituted hydroxypropylcellulose, and talc.
Lead Sponsor
Evergreen Therapeutics, Inc.
INDUSTRY